Literature DB >> 1320571

Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints.

F M Brennan1, D L Gibbons, T Mitchell, A P Cope, R N Maini, M Feldmann.   

Abstract

We previously proposed the hypothesis that the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) plays a pivotal role in the pathogenesis of rheumatoid arthritis (RA) based on our observations that it is the dominant inducer of interleukin-1 (IL-1) and granulocyte-macrophage colony-stimulating factor (GM-CSF) production in RA synovial joint mononuclear (MNC) cells in culture. Since TNF-alpha acts via two membrane receptors, we have extended those studies to investigate the distribution of the p55 and p75 TNF receptors (TNF-R) in RA tissue. Surface receptor expression was quantitated by flow cytometry using monoclonal antibodies specific to the p55 (HTR-9) and the p75 (UTR-1) TNF-R. Both receptors were significantly increased on MNC isolated from the synovial membrane of RA patients compared to normal or RA peripheral blood MNC. Interestingly, the p75 TNF-R was increased both on large monocytic/macrophage-type cells and CD3+ lymphocytes. Furthermore, there was a significant increase in the proportion of CD3+ cells in RA synovial fluid expressing the p75 TNF-R, compared to matched peripheral blood MNC. In contrast to RA synovial MNC, p75 or p55 TNF-R expression was not significantly increased in osteoarthritis synovial MNC. In addition, Northern blot analysis indicated abundant expression of both p55 and p75 mRNA in RA synovial joint MNC. This was in contrast to normal peripheral blood MNC cells which contained little or no constitutive TNF-R mRNA; following stimulation with phytohemagglutinin and IL-2, a rapid and transient expression of both receptor mRNA was induced. These results, therefore, indicate that in RA synovial joint tissue there is up-regulation of both p55 and p75 TNF-R mRNA and surface protein expression, and with the presence of TNF-alpha in RA tissues, these results provide support to our hypothesis that TNF-alpha is of critical importance in the pathogenesis of RA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1320571     DOI: 10.1002/eji.1830220734

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  21 in total

1.  Intravitreal treatment with antisense oligonucleotides targeting tumor necrosis factor-α in murine herpes simplex virus type 1 retinitis.

Authors:  Rafael S Grajewski; Jin Li; Susanne Wasmuth; Maren Hennig; Dirk Bauer; Arnd Heiligenhaus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-11-10       Impact factor: 3.117

2.  C5orf30 is a negative regulator of tissue damage in rheumatoid arthritis.

Authors:  Munitta Muthana; Sarah Hawtree; Adam Wilshaw; Eimear Linehan; Hannah Roberts; Sachin Khetan; Gbadebo Adeleke; Fiona Wright; Mohammed Akil; Ursula Fearon; Douglas Veale; Barbara Ciani; Anthony G Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-27       Impact factor: 11.205

Review 3.  The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis.

Authors:  G Camussi; E Lupia
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

4.  Encapsulation in hollow fibres of xenogeneic cells engineered to secrete IL-4 or IL-13 ameliorates murine collagen-induced arthritis (CIA).

Authors:  N Bessis; J Honiger; D Damotte; A Minty; C Fournier; D Fradelizi; M Boissier
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

5.  Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures.

Authors:  L M Williams; D L Gibbons; A Gearing; R N Maini; M Feldmann; F M Brennan
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

6.  Increased expression and occupancy of receptors for tumour necrosis factor on blood monocytes from tuberculosis patients.

Authors:  J Cadranel; C Philippe; B Philippe; B Milleron; B Fouqueray; C Mayaud; L Baud
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

7.  Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses.

Authors:  S Stephens; S Emtage; O Vetterlein; L Chaplin; C Bebbington; A Nesbitt; M Sopwith; D Athwal; C Novak; M Bodmer
Journal:  Immunology       Date:  1995-08       Impact factor: 7.397

8.  Critical role of peripheral blood phagocytes and the involvement of complement in tumour necrosis factor enhancement of passive collagen-arthritis.

Authors:  R A Fava; C Gates; A S Townes
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

9.  Soluble TNF receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to TNF.

Authors:  A P Cope; D Aderka; D Wallach; M Kahan; N R Chu; F M Brennan; M Feldmann
Journal:  Immunology       Date:  1995-01       Impact factor: 7.397

10.  Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis.

Authors:  A P Cope; M Londei; N R Chu; S B Cohen; M J Elliott; F M Brennan; R N Maini; M Feldmann
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.